Deutsche Bank Ag\ Syndax Pharmaceuticals Inc Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Deutsche Bank Ag\ holds 66,270 shares of SNDX stock, worth $866,811. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,270

Previous 53,189 24.59%

Holding current value

$866,811

Previous $1.09 Million 16.87%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$17.93 - $24.81 $234,542 - $324,539	13,081 Added 24.59%	66,270 $1.28 Million
Q2 2024 Aug 14, 2024	SELL	$18.82 - $23.79 $58,078 - $73,415	-3,086 Reduced 5.48%	53,189 $1.09 Million
Q1 2024 May 15, 2024	BUY	$19.71 - $24.57 $154,073 - $192,063	7,817 Added 16.13%	56,275 $1.34 Million
Q4 2023 Feb 14, 2024	SELL	$11.39 - $21.67 $15,433 - $29,362	-1,355 Reduced 2.72%	48,458 $1.05 Million
Q3 2023 Nov 09, 2023	BUY	$14.52 - $21.77 $87,657 - $131,425	6,037 Added 13.79%	49,813 $723,000
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $258,670 - $298,240	-13,368 Reduced 23.39%	43,776 $916,000
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $280,128 - $392,939	13,559 Added 31.11%	57,144 $1.21 Million
Q4 2022 Feb 13, 2023	BUY	$20.64 - $26.24 $344,791 - $438,339	16,705 Added 62.15%	43,585 $1.11 Million
Q3 2022 Nov 14, 2022	SELL	$18.51 - $24.79 $103,359 - $138,427	-5,584 Reduced 17.2%	26,880 $646,000
Q2 2022 Aug 11, 2022	BUY	$13.64 - $19.48 $18,973 - $27,096	1,391 Added 4.48%	32,464 $625,000
Q1 2022 May 13, 2022	BUY	$14.84 - $22.15 $14,691 - $21,928	990 Added 3.29%	31,073 $540,000
Q4 2021 Feb 11, 2022	BUY	$15.23 - $22.47 $20,804 - $30,694	1,366 Added 4.76%	30,083 $659,000
Q3 2021 Nov 04, 2021	SELL	$13.87 - $19.8 $24,078 - $34,372	-1,736 Reduced 5.7%	28,717 $548,000
Q2 2021 Aug 11, 2021	BUY	$13.42 - $25.18 $107,829 - $202,321	8,035 Added 35.84%	30,453 $523,000
Q1 2021 May 13, 2021	BUY	$19.28 - $24.59 $13,380 - $17,065	694 Added 3.19%	22,418 $501,000
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $104,688 - $183,308	6,933 Added 46.87%	21,724 $483,000
Q3 2020 Nov 12, 2020	SELL	$13.39 - $17.48 $181,929 - $237,500	-13,587 Reduced 47.88%	14,791 $218,000
Q2 2020 Aug 13, 2020	BUY	$8.94 - $20.98 $180,588 - $423,796	20,200 Added 247.0%	28,378 $421,000
Q1 2020 May 14, 2020	BUY	$6.65 - $12.03 $2,819 - $5,100	424 Added 5.47%	8,178 $90,000
Q4 2019 Feb 14, 2020	BUY	$5.43 - $9.22 $7,466 - $12,677	1,375 Added 21.56%	7,754 $67,000
Q3 2019 Nov 14, 2019	SELL	$7.47 - $10.76 $73,609 - $106,029	-9,854 Reduced 60.7%	6,379 $46,000
Q2 2019 Aug 14, 2019	SELL	$4.9 - $9.31 $9,133 - $17,353	-1,864 Reduced 10.3%	16,233 $150,000
Q1 2019 May 15, 2019	SELL	$4.26 - $6.86 $834 - $1,344	-196 Reduced 1.07%	18,097 $94,000
Q4 2018 Feb 14, 2019	SELL	$3.6 - $8.42 $251,712 - $588,726	-69,920 Reduced 79.26%	18,293 $81,000
Q3 2018 Dec 21, 2021	BUY	$6.33 - $8.08 $44,727 - $57,093	7,066 Added 8.71%	88,213 $712,000
Q3 2018 Nov 14, 2018	BUY	$6.33 - $8.08 $277,937 - $354,776	43,908 Added 117.91%	81,147 $655,000
Q2 2018 Apr 21, 2020	BUY	$6.93 - $14.63 $54,067 - $114,143	7,802 Added 26.5%	37,239 $262,000
Q2 2018 Aug 14, 2018	SELL	$6.93 - $14.63 $104,407 - $220,415	-15,066 Reduced 33.85%	29,437 $205,000
Q1 2018 Oct 18, 2019	BUY	$8.71 - $14.82 $49,699 - $84,562	5,706 Added 14.71%	44,503 $632,000
Q1 2018 May 15, 2018	SELL	$8.71 - $14.82 $30,293 - $51,543	-3,478 Reduced 8.23%	38,797 $551,000
Q4 2017 Feb 14, 2018	BUY	$7.8 - $12.94 $134,261 - $222,736	17,213 Added 68.68%	42,275 $369,000
Q3 2017 Nov 14, 2017	BUY	$10.9 - $12.73 $273,175 - $319,039	25,062	25,062 $290,000

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account